

CITATION REPORT

List of articles citing

Hydroxychloroquine: a multifaceted treatment in lupus

DOI: 10.1016/j.lpm.2014.03.007
Presse Medicale, 2014, 43, e167-80.

Source: <https://exaly.com/paper-pdf/59747337/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
139	Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. 2015 , 1, FSO26		21
138	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. 2015 , 67, 2176-84		87
137	Autophagy in cancer. 2015 , 7, 18		67
136	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. 2015 , 70, 1608-21		258
135	Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus. 2015 , 73, e79		5
134	AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. 2015 , 349, 436-40		413
133	Systemic lupus erythematosus and thrombosis. 2015 , 13, 16		38
132	Metal-free domino one-pot protocols for quinoline synthesis. 2015 , 5, 42020-42053		113
131	Stem cell therapies for systemic lupus erythematosus: current progress and established evidence. 2015 , 11, 763-9		5
130	[Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients]. 2015 , 38, 377-87		1
129	Chloroquine-based hybrid molecules as promising novel chemotherapeutic agents. 2015 , 762, 472-86		24
128	Immunomodulators in SLE: Clinical evidence and immunologic actions. 2016 , 74, 73-84		54
127	Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions. 2016 , 100, 719-31		11
126	CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. 2016 , 128, 1037-42		84
125	Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. 2016 , 23, 67-75		32
124	Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. 2016 , 81, 835-48		56
123	Cardiovascular Issues in SLE. 2016 , 133-145		

122	Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. 2016 , 118, 560-573	20
121	Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. 2016 , 74, 182-193	100
120	Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. 2016 , 55, 1623-30	24
119	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. 2016 , 75, 2014-2021	132
118	Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. 2016 , 47, 183-93	14
117	Genomics of Immune Diseases and New Therapies. 2016 , 34, 121-49	32
116	Rheumatic Diseases of Childhood. 2016 , 112-123.e1	1
115	[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]. 2017 , 76, 27-32	0
114	Hydroxychloroquine retinopathy. 2017 , 31, 828-845	99
113	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. 2017 , 16, 650-657	19
112	Pro-inflammatory Ca-activated K channels are inhibited by hydroxychloroquine. 2017 , 7, 1892	19
111	Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. 2017 , 158, 1538-1545	11
110	Hydroxychloroquine in systemic lupus erythematosus (SLE). 2017 , 16, 411-419	153
109	Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. 2017 , 76, 891-897	55
108	Treat to target, remission and low disease activity in SLE. 2017 , 31, 342-350	16
107	Energy efficient Pfitzinger reaction: a novel strategy using a surfactant catalyst. 2017 , 41, 12380-12383	10
106	Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients. 2017 , 39, 1-6	7
105	Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus. 2017 , 69, 1201-1208	18

104	Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. 2018 , 33, 1604-1610		18
103	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. 2017 , 617-643		0
102	NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils. 2016 , 7, 678		33
101	Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. 2017 , 13, 583-592		12
100	Treatment of Systemic Lupus Erythematosus. 2017 , 1368-1388.e5		3
99	Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work. 2018 , 45, 344-348		12
98	Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl. 2018 , 9, 4		6
97	Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. <i>Lupus</i> , 2018 , 27, 265-272	2.6	22
96	Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk. 2018 , 77, e59		8
95	Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 753-761	2.6	8
94	Mimickers of neuropsychiatric manifestations in systemic lupus erythematosus. 2018 , 32, 623-639		7
93	Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. 2018 , 20, 249		3
92	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. 2018 , 5, e000287		7
91	Up-Regulation of TLR7-Mediated IFN- β Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. 2018 , 9, 1957		31
90	Using hydroxychloroquine and protecting the retina. <i>Lupus</i> , 2018 , 27, 1399-1401	2.6	1
89	[Lupus nephritis]. 2018 , 77, 593-608		4
88	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. 2018 , 12, 1685-1695		53
87	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. 2018 , 38, 653-671		152

86	[How to minimize the risk of infection in systemic lupus erythematosus?]. <i>Revue De Medecine Interne</i> , 2019 , 40, 347-350	0.1	0
85	Preclinical and early systemic lupus erythematosus. 2019 , 33, 101422		9
84	Hydroxychloroquine-induced podocytopathy mimicking Fabry disease. 2019 , 12,		8
83	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. 2019 , 18, 415-425		15
82	Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing. 2019 , 10, 578		23
81	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN γ Production From Patients Affected With Cutaneous Lupus Erythematosus. 2019 , 10, 275		19
80	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. 2019 , 41, 476-482		10
79	Lupus and Infections. 2019 , 543-555		2
78	Antiphospholipid Syndrome. 2019 , 374-395		
77	Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. 2020 , 58, 194-212		10
76	Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. 2020 , 40, 777-783		3
75	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. 2020 , 22, 223		5
74	Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. 2020 , 2020, 4582612		9
73	Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. 2020 , 16, 617-629		24
72	Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. 2020 , 21, 469		4
71	Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20975904	38	6
70	Rheumatologists' perspective on hydroxychloroquine guidelines. 2020 , 7,		1
69	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. 2020 , 369, m1844		266

68	Advancements in the synthesis of fused tetracyclic quinoline derivatives.. 2020 , 10, 19867-19935		17
67	Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. 2020 , 2020, 2943848		4
66	Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications. 2020 , 34, 1589-1592		16
65	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32		24
64	Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review. 2020 , 5,		21
63	Is hydroxychloroquine beneficial for COVID-19 patients?. 2020 , 11, 512		57
62	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. 2020 , 50, 1150-1157		29
61	Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. <i>Lupus</i> , 2020 , 29, 273-282	2.6	5
60	Hydroxychloroquine and "off-label" utilization in the treatment of oral conditions. 2020 , 129, 643-644		4
59	[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. <i>Revue De Medecine Interne</i> , 2020 , 41, 335-338	0.1	3
58	Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients. 2021 , 131, E957-E960		2
57	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. 2021 , 35, 343-348		7
56	Kinetics and a mechanistic investigation of 2H-thiopyrano [2, 3-b] quinoline-2, 3-dicarboxylates from 2-mercaptoquinoline-3-carbaldehydes, dialkyl acetylenedicarboxylates and triphenylphosphine: Empirical approach. 2021 , 196, 300-310		
55	UHPLC-MS/MS Method for Determination of Hydroxychloroquine and Its Main Metabolites in Oral Fluid and Whole Blood for Therapeutic Drug Monitoring. 2021 , 6, 868-880		0
54	A data-driven pipeline to extract potential side effects through co-prescription analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up.		
53	Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. 2021 , 8,		2
52	Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 1378-1384	2.6	
51	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. 2021 , 17,		0

50	Antimalarial-induced retinal toxicity. 2021 , 28, 132-132		0
49	Hyperglycémie, hydroxychloroquine et SARS-CoV-2. 2021 , 2, 229		1
48	Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis. 2021 , 51, 237-245		1
47	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. 2020 , 83, 579-586		16
46	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. 2020 , 59, 3807-3816		10
45	The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. 2021 , 33, 211-218		3
44	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. 2020 , 12, e12476		29
43	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. 2020 , 26, 4467-4485		17
42	Primary Sjögren's Syndrome and Cardiovascular Disease. 2020 , 18, 447-454		11
41	Drug Repositioning for COVID-19. 2020 , 51, e4279		3
40	Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. 2017 , 28, 4-12		23
39	Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology. <i>Indian Journal of Dermatology</i> , 2016 , 61, 469-81	0.9	39
38	Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. <i>Reumatologia</i> , 2020 , 58, 390-400	1.7	2
37	Treatments. 2018 , 85-107		
36	Tissue distribution and tumor concentrations of hydroxychloroquine and quinacrine analogs in mice.		1
35	Itchy Violaceous Plaques. 2020 , 329-335		
34	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Hydroxychloroquine in Healthy Volunteers.		2
33	The Potential Benefit of Hydroxychloroquine in Chronic Placental Inflammation of Unknown Etiology Associated with Adverse Pregnancy Outcomes.. <i>Healthcare (Switzerland)</i> , 2022 , 10,	3.4	0

32	Clinical and immunological features of chronic ulcerative stomatitis: a systematic review.. <i>Journal of Oral Pathology and Medicine</i> , 2022 ,	3.3	0
31	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
30	Practical management of patients on hydroxychloroquine.. <i>Joint Bone Spine</i> , 2021 , 88, 105316	2.9	0
29	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis.. <i>Lupus</i> , 2021 , 9612033211062515	3.2	1
28	Image_1.TIF. 2019 ,		
27	Image_2.TIF. 2019 ,		
26	Image_3.TIF. 2019 ,		
25	Image_4.TIF. 2019 ,		
24	Image_5.TIF. 2019 ,		
23	Table_1.xlsx. 2019 ,		
22	Presentation_1.PPTX. 2018 ,		
21	Presentation_2.PPTX. 2018 ,		
20	Presentation_3.PPTX. 2018 ,		
19	Presentation_4.PPTX. 2018 ,		
18	Presentation_5.PPTX. 2018 ,		
17	Presentation_6.PPTX. 2018 ,		
16	Presentation_7.PPTX. 2018 ,		
15	Presentation_8.PPTX. 2018 ,		

14	Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. <i>Trials</i> , 2022 , 23,	2.8	
13	Intérêt des dosages pharmacologiques d'immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. <i>Revue De Medecine Interne</i> , 2022 ,	0.1	1
12	Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells via up-regulation of CD81 contributing to alleviate lupus symptoms. <i>Molecular Medicine</i> , 2022 , 28,	6.2	0
11	Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. <i>Expert Opinion on Biological Therapy</i> , 2022 , 22, 821-829	5.4	1
10	Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. 2022 , 17, e0272034		0
9	Stress, mindfulness, and systemic lupus erythematosus: An overview and directions for future research. 096120332211229		
8	Rapid Onset and Resolution of Hydroxychloroquine Cardiomyopathy: A Case Report. 2022 , 2022, 1-4		0
7	Nierenbeteiligung bei Kollagenosen.		0
6	Halofuginone ameliorates systemic lupus erythematosus by targeting Blk in myeloid-derived suppressor cells. 2023 , 114, 109487		0
5	Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. 2023 , 59, 56		0
4	Screening for toxic retinopathy due to antimalarial drugs in Tunisia. 2023 , 46, 356-362		0
3	New Progress in the Treatment of IgA Nephropathy. 2023 , 13, 2272-2285		0
2	Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review. 2023 , 15, 1036		1
1	Les intelligences artificielles conversationnelles en médecine interne : l'exemple de l'hydroxychloroquine selon ChatGPT. 2023 ,		0